乙基[6-(甲基氨基)-2-吡啶基]乙酸酯 | 205676-86-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 乙基[6-(甲基氨基)-2-吡啶基]乙酸酯
• 中文别名: 2-(6-(甲基氨基)吡啶-2-基)乙酸乙酯
• 英文名称: ethyl 2-[6-(methylamino)-2-pyridyl]acetate
• 英文别名: ethyl 2-[6-(methylamino)-pyridin-2-yl]acetate；Ethyl-6-(methylamino)-2-pyridylacetate；Ethyl 2-(6-(methylamino)pyridin-2-yl)acetate；ethyl 2-[6-(methylamino)pyridin-2-yl]acetate
• CAS: 205676-86-4
• 化学式: C₁₀H₁₄N₂O₂
• mdl: MFCD09029732
• 分子量: 194.233
• InChiKey: HLVIMVSZRPVEPN-UHFFFAOYSA-N

物化性质

• 沸点：
  306.3±32.0 °C(Predicted)
• 密度：
  1.133±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  ——	ethyl 2-{6-[(tert-butoxy)-N-methylcarbonylamino]-2-pyridyl}acetate	205676-85-3	C15H22N2O4	294.351

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  6-(甲基氨基)-2-吡啶乙醇	2-methylamino-6-(2-hydroxyethyl)pyridine	205676-87-5	C8H12N2O	152.196

反应信息

• 作为反应物：
  描述：

  乙基[6-(甲基氨基)-2-吡啶基]乙酸酯 在 lithium aluminium tetrahydride 、 硫酸 、 四丁基氟化铵 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 ethyl 3-(6-{2-[6-(methylamino)-2-pyridyl]ethoxy}benzo[b]furan-3-yl)propanoate
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Novel Potent and Selective α_vβ₃/α_vβ₅ Integrin Dual Inhibitors with Improved Bioavailability. Selection of the Molecular Core

  摘要：

  A novel series of potent and selective alpha(v)beta(3)/alpha(v)beta(5) dual inhibitors was designed, synthesized, and evaluated against several integrins. These compounds were synthesized through a Mitsunobu reaction between the guanidinium mimetics and the corresponding central templates. Guanidinium mimetics with enhaced rigidity (i.e., (2-pyridylamino)propoxy versus the 2-(6-methylamino-2-pyridyl)ethoxy) led to improved activity toward alpha(v)beta(3). Exemplary oral bioavailability in mice was achieved using the indole central scaffold. Although, oral bioavailability was maintained when the indole molecular core was replace with the bioisosteric benzofuran or benzothiophene ring systems, it was found to not significantly impact the integrin activity or selectivity. However, the indole series displayed the best in vivo pharmacokinetic properties. Thus, the indole series was selected for further structure-activity relationships to obtain more potent alpha(v)beta(3)/alpha(v)beta(5) dual antagonist with improved oral bioavailability.

  DOI：

  10.1021/jm049725u
• 作为产物：
  描述：

  6-甲基吡啶-2-氨基甲酸叔丁酯 在 sodium hydride 、 三氟乙酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 37.75h， 生成 乙基[6-(甲基氨基)-2-吡啶基]乙酸酯
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Novel Potent and Selective α_vβ₃/α_vβ₅ Integrin Dual Inhibitors with Improved Bioavailability. Selection of the Molecular Core

  摘要：

  A novel series of potent and selective alpha(v)beta(3)/alpha(v)beta(5) dual inhibitors was designed, synthesized, and evaluated against several integrins. These compounds were synthesized through a Mitsunobu reaction between the guanidinium mimetics and the corresponding central templates. Guanidinium mimetics with enhaced rigidity (i.e., (2-pyridylamino)propoxy versus the 2-(6-methylamino-2-pyridyl)ethoxy) led to improved activity toward alpha(v)beta(3). Exemplary oral bioavailability in mice was achieved using the indole central scaffold. Although, oral bioavailability was maintained when the indole molecular core was replace with the bioisosteric benzofuran or benzothiophene ring systems, it was found to not significantly impact the integrin activity or selectivity. However, the indole series displayed the best in vivo pharmacokinetic properties. Thus, the indole series was selected for further structure-activity relationships to obtain more potent alpha(v)beta(3)/alpha(v)beta(5) dual antagonist with improved oral bioavailability.

  DOI：

  10.1021/jm049725u

文献信息

• Method for stimulating bone formation
  申请人：SmithKline Beecham Corporation

  公开号：US20020032187A1

  公开（公告）日：2002-03-14

  A method for stimulating bone formation by administering integrin binding compounds which cause the release of osteocalcin from osteoblasts is disclosed.

  通过给予能够引发骨细胞释放骨钙蛋白的整合素结合化合物来刺激骨形成的方法被揭示。
• Vitronectin receptor antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US20030125317A1

  公开（公告）日：2003-07-03

  Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.

  本文披露了具有苯二氮卓环核结构的化合物，这些化合物是维腾蛋白受体拮抗剂，可用于治疗骨质疏松症、血管生成、肿瘤生长和转移、动脉粥样硬化、再狭窄和炎症。
• Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20030018064A1

  公开（公告）日：2003-01-23

  The present invention relates to novel substituted benzofurans and benzothiophenes compounds that are antagonists of alpha V (&agr;v) integrins, for example &agr; v &bgr; 3 and &agr; v &bgr; 5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by &agr; v &bgr; 3 and &agr; v &bgr; 5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula I: 1 where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , m, n, i, j and k are defined herein.

  本发明涉及一种新的取代苯并呋喃和苯并噻吩化合物，它们是αV（αv）整合素的拮抗剂，例如αvβ3和αvβ5整合素，其药学上可接受的盐以及其药物组合物。这些化合物可用于治疗由αvβ3和αvβ5整合素介导的病理条件，包括肿瘤生长、转移、再狭窄、骨质疏松、炎症、黄斑变性、糖尿病性视网膜病变和类风湿性关节炎等疾病。这些化合物具有通用的化学式I：1，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、m、n、i、j和k在此处被定义。
• SUBSTITUTED BENZOFURANS AND BENZOTHIOPHENES, METHODS OF MAKING AND METHODS OF USE AS INTEGRIN ANTAGONISTS
  申请人：3-DIMENSIONAL PHARMACEUTICALS, INC.

  公开号：EP1390362A1

  公开（公告）日：2004-02-25
• US6872730B2
  申请人：——

  公开号：US6872730B2

  公开（公告）日：2005-03-29